News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novozymes A/S (NZYMb.CO)' New CEO Takes Office


4/1/2013 6:23:01 AM

COPENHAGEN, DENMARK – April 1, 2013 - Today, Peder Holk Nielsen takes office as President & CEO of Novozymes. “I am proud and honored to lead this great company forward,” says Peder Holk Nielsen. “Novozymes is in a very strong position, and we will continue with our overall strategy. Our success rests on our ability to bring new innovation to our customers, and our ability to find new ways biotechnology can help them improve their products and make more with less. A key focus for me will be to make sure we bring these innovations to the market even faster than we do today.”

Peder Holk Nielsen, 56, has played a central role in the development of Novozymes in its current form. His 28-year career in Novozymes and Novo Industri/Novo Nordisk spans management positions across business development, research and development, quality management and sales and marketing. Up until his appointment as CEO, he served as Executive Vice President and Head of Enzyme Business from 2007-2013.

Peder Holk Nielsen takes over as CEO from Steen Riisgaard, who steps down after 12 years in the company’s top post and 33 years in Novozymes and Novo Industri/Novo Nordisk.

New executive leadership team

The appointment of Peder Holk Nielsen as Novozymes’ new CEO was announced on January 21, 2013, in connection with the company’s full year earnings report.

Novozymes’ Executive Leadership Team as of April 1, 2013:

President & CEO: Peder Holk Nielsen

Business Development: EVP Thomas Videbæk

Business Operations: EVP Andrew Fordyce

Supply Operations: EVP Thomas Nagy

Research & Development: EVP Per Falholt

Corporate Functions: EVP and CFO Benny D. Loft

The executive management is joined by Andrew Fordyce, 49, former Vice President of Sales and Customer Solutions.

Read more about the executive leadership team.

On January 21, Novozymes also announced new long-term financial targets for the next five years:

• Average organic sales growth of more than 10% (from 2015 onward)

• EBIT margin of more than 24%

• Return on invested capital of more than 22%

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.

MEDIA CONTACTS

Europe

Nour Amrani

Office: +32 2 234 6121

Mobile: +32 487 546 322

nuam@novozymes.com

Denmark

René Tronborg

Office: +45 44462274

Mobile: +45 30772274

retr@novozymes.com

US

Paige Donnelly

Office: +1 919 494 3209

Mobile: +1 919 218 4501

pagd@novozymes.com

China

Lian Meng

Office: +86 106 298 7888+392

Mobile: +86 136 992 31164

mexl@novozymes.com

Brazil

Henrique Pellini

Office: +55 41 36411000

Mobile: +55 41 9288-0282

hqp@novozymes.com

India

Poonam Kapila

Mobile: +91 9910822339

poka@novozymes.com

INVESTOR CONTACTS

Europe

Martin Riise

Office: +45 4446 0738

Mobile: +45 3077 0738

mrsn@novozymes.com

US

Thomas Steenbech Bomhoff

Office: +1 9194943483

Mobile: +1 9196492565

tsbm@novozymes.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES